ווטריינט 200 מ"ג
Country: Israel
Language: Hebrew
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
PAZOPANIB AS HYDROCHLORIDE 200 MG
Available from:
GLAXO SMITH KLINE (ISRAEL) LTD
ATC code:
L01XE11
Pharmaceutical form:
FILM COATED TABLETS
Administration route:
PER OS
Manufactured by:
GLAXO OPERATIONS UK LIMITED
Therapeutic group:
PAZOPANIB
Therapeutic indications:
Renal cell carcinoma (RCC)Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
Authorization date:
2011-01-01
